Search results
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views - Tyson Foods (NYSE:TSN)
Benzinga· 4 days agoShares of GlycoMimetics, Inc GLYC were down 79% to $0.3831 after the company announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute ...
In case you missed it in The Sun the week of April 29, 2024
The Jamestown Sun, N.D. via Yahoo News· 5 days agoMay 4—The following stories from this week appeared on www.jamestownsun.com and in The Jamestown Sun. City beautification project brightens railroad crossing in Jamestown A city beautification ...
Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results
GuruFocus.com via Yahoo Finance· 6 days agoThe company completed additional enrollment for its TP53 mutant Acute Myeloid Leukemia cohorts and is gearing up for new trials in Myelodysplastic ...
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com
ETF DAILY NEWS· 3 days agoAnalysts at StockNews.com began coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a report issued on Tuesday. The brokerage set a “buy” rating on the stock. Other equities ...
Kura Oncology (NASDAQ:KURA) Rating Reiterated by Wedbush
ETF DAILY NEWS· 5 days agoKura Oncology (NASDAQ:KURA – Get Free Report)‘s stock had its “outperform” rating reissued by Wedbush in a note issued to investors on Friday, Benzinga reports. Wedbush’s price target would ...
Q1 2024 EPS Estimates for GlycoMimetics, Inc. (NASDAQ:GLYC) Lowered by HC Wainwright
ETF DAILY NEWS· 2 days agoGlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) – HC Wainwright dropped their Q1 2024 EPS estimates for GlycoMimetics in a report released on Monday, May 6th. HC Wainwright analyst E. White ...
Cullinan Oncology (NASDAQ:CGEM) Now Covered by Stifel Nicolaus
ETF DAILY NEWS· 7 days agoAnalysts at Stifel Nicolaus initiated coverage on shares of Cullinan Oncology (NASDAQ:CGEM – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set ...
Analysts Offer Predictions for Actinium Pharmaceuticals, Inc.’s Q2 2024 Earnings (NYSEAMERICAN:ATNM)
ETF DAILY NEWS· 3 days agoActinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Free Report) – Research analysts at B. Riley issued their Q2 2024 earnings per share estimates for Actinium Pharmaceuticals in a research ...
Jazz Pharmaceuticals (NASDAQ:JAZZ) Receives “Buy” Rating from Needham & Company LLC
ETF DAILY NEWS· 4 days agoNeedham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report released on Thursday morning, Benzinga reports. Needham & Company ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoFirst-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of
